search
Back to results

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

Primary Purpose

Sarcoma, Kaposi, HIV Infections

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Doxorubicin hydrochloride (liposomal)
Bleomycin sulfate
Vincristine sulfate
Sponsored by
Sequus Pharmaceuticals
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sarcoma, Kaposi focused on measuring Vincristine, Sarcoma, Kaposi, Liposomes, Doxorubicin, Drug Therapy, Combination, Acquired Immunodeficiency Syndrome, Bleomycin, Drug Carriers

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria Concurrent Medication: Allowed: Prophylaxis for PCP, cryptococcal, and herpes infections, and antiretroviral therapy (e.g., AZT, ddC, ddI) provided these doses have been stable for at least 1 month. Maintenance therapy for tuberculosis, fungal, and herpes infections. Therapy for new episodes of tuberculosis, fungal, and herpes infection except with potentially myelotoxic chemotherapy. Foscarnet for cytomegalovirus infection. Erythropoietin. Patients must have: Biopsy-proven, progressive, AIDS-related Kaposi's sarcoma, with any of the following: At least 15 mucocutaneous lesions. Six or more new lesions in the prior month. Documented visceral disease with at least five accessible cutaneous lesions. Documented anti-HIV antibody. No active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, Pneumocystis carinii, or other microorganisms (if REQUIRING treatment with myelotoxic drugs). Life expectancy > 4 months. NOTE: Patients who fail the BV combination or who relapse are eligible to enter the Liposome Technology open trial using DOX-SL alone. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Clinically significant cardiac disease. Confusion, disorientation, CNS symptoms, or peripheral neuropathy. Concurrent Medication: Excluded: Other cytotoxic chemotherapy. Colony-stimulating factors. Ganciclovir. Patients with the following prior conditions are excluded: Prior neoplasms treated with extensive chemotherapy that, in the investigator's opinion, has led to irreversibly compromised bone marrow function. History of idiosyncratic or allergic reaction to anthracyclines, bleomycin, or vincristine. History of major psychiatric illness. Prior Medication: Excluded: Cytotoxic chemotherapy or interferon therapy within the past 4 weeks. More than one prior cycle of bleomycin/vincristine at any time. Prior Treatment: Excluded: Radiation or electron beam therapy within the past 3 weeks.

Sites / Locations

  • Beth Israel Hosp
  • Mount Sinai Med Ctr
  • Twelve Oaks Hosp
  • Virginia Mason Research Center / Clinical Trial Unit

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 2, 1999
Last Updated
June 23, 2005
Sponsor
Sequus Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00002105
Brief Title
Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
Official Title
Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
Study Type
Interventional

2. Study Status

Record Verification Date
January 1996
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Sequus Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy BV (bleomycin/vincristine). To evaluate the safety and tolerance of DOX-SL compared to BV in a population of AIDS patients with moderate to severe KS.
Detailed Description
Patients are randomized to receive either DOX-SL or the BV combination. Infusions are given on day 1 and every 3 weeks for a total of six cycles. Kaposi's sarcoma lesions are evaluated prior to every cycle, at the end of the last treatment cycle, and 4 weeks following the end of the last treatment. Patients who respond to therapy will be followed every 2 months for up to 1 year. Patients must agree to have one or more representative KS lesions biopsied.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcoma, Kaposi, HIV Infections
Keywords
Vincristine, Sarcoma, Kaposi, Liposomes, Doxorubicin, Drug Therapy, Combination, Acquired Immunodeficiency Syndrome, Bleomycin, Drug Carriers

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Enrollment
220 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Doxorubicin hydrochloride (liposomal)
Intervention Type
Drug
Intervention Name(s)
Bleomycin sulfate
Intervention Type
Drug
Intervention Name(s)
Vincristine sulfate

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Prophylaxis for PCP, cryptococcal, and herpes infections, and antiretroviral therapy (e.g., AZT, ddC, ddI) provided these doses have been stable for at least 1 month. Maintenance therapy for tuberculosis, fungal, and herpes infections. Therapy for new episodes of tuberculosis, fungal, and herpes infection except with potentially myelotoxic chemotherapy. Foscarnet for cytomegalovirus infection. Erythropoietin. Patients must have: Biopsy-proven, progressive, AIDS-related Kaposi's sarcoma, with any of the following: At least 15 mucocutaneous lesions. Six or more new lesions in the prior month. Documented visceral disease with at least five accessible cutaneous lesions. Documented anti-HIV antibody. No active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, Pneumocystis carinii, or other microorganisms (if REQUIRING treatment with myelotoxic drugs). Life expectancy > 4 months. NOTE: Patients who fail the BV combination or who relapse are eligible to enter the Liposome Technology open trial using DOX-SL alone. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Clinically significant cardiac disease. Confusion, disorientation, CNS symptoms, or peripheral neuropathy. Concurrent Medication: Excluded: Other cytotoxic chemotherapy. Colony-stimulating factors. Ganciclovir. Patients with the following prior conditions are excluded: Prior neoplasms treated with extensive chemotherapy that, in the investigator's opinion, has led to irreversibly compromised bone marrow function. History of idiosyncratic or allergic reaction to anthracyclines, bleomycin, or vincristine. History of major psychiatric illness. Prior Medication: Excluded: Cytotoxic chemotherapy or interferon therapy within the past 4 weeks. More than one prior cycle of bleomycin/vincristine at any time. Prior Treatment: Excluded: Radiation or electron beam therapy within the past 3 weeks.
Facility Information:
Facility Name
Beth Israel Hosp
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Mount Sinai Med Ctr
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Twelve Oaks Hosp
City
Houston
State/Province
Texas
ZIP/Postal Code
77074
Country
United States
Facility Name
Virginia Mason Research Center / Clinical Trial Unit
City
Seattle
State/Province
Washington
ZIP/Postal Code
98101
Country
United States

12. IPD Sharing Statement

Citations:
Citation
Stewart S, Jablonowski H, Goebel FD, L'Age M, Spittle M, Luthy R. Randomized comparative trial of DOXIL vs. Bleomycin and Vincristine in the treatment of AIDS-Related KS. Int Conf AIDS. 1996 Jul 7-12;11(Program Supplement):27 (abstract no LBB6026)
Results Reference
background

Learn more about this trial

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

We'll reach out to this number within 24 hrs